Immunotherapy and chemotherapy for newly diagnosed NK/T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have newly diagnosed extranodal NK/T-cell lymphoma (a rare cancer of immune cells), confirmed by biopsy
- Your cancer is in the nasal cavity or upper throat area and is stage I or II (early stages)
- You have not received any prior chemotherapy, though short-term steroids for symptom relief are okay
- You are in good enough health to tolerate treatment (ECOG performance status 0–2, meaning you can do daily activities)
- You have adequate organ and bone marrow function (normal enough kidney, liver, and blood cell counts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three medicines (sintilimab, chidamide, and azacitidine) to treat a rare blood cancer called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination can control the cancer better than traditional approaches.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
Hear when a new NKTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.